Literature DB >> 21458581

PGE(2) decreases muscle cell proliferation in patients with non-asthmatic eosinophilic bronchitis.

Beatriz Sastre1, Mar Fernández-Nieto, Esther López, Cristina Gámez, Erica Aguado, Santiago Quirce, Victoria del Pozo, Joaquín Sastre.   

Abstract

Non-asthmatic eosinophilic bronchitis (NAEB) is characterized by chronic cough and sputum eosinophilia without bronchial hyperresponsiveness. The aim of the present study is to determine whether increased levels of PGE(2) from NAEB sputum supernatants play a protective role in airway inflammation and muscular hyperplasia. Twenty-one patients with NAEB, 15 asthmatic patients, and 12 healthy subjects were studied. An up-regulated PGE(2) enzymatic pathway was observed in bronchial biopsies from patients with NAEB as compared with samples from asthmatic patients. Also, EP2 and EP4 receptor expression was increased in these samples. BSMC proliferation was inhibited to a greater extent in NAEB sputum supernatants than in those taken from asthmatic subjects and healthy controls. This inhibition was mostly due to PGE(2) levels, a fact which was confirmed by employing synthetic EP2 and EP4 agonist and antagonist receptors.These findings suggest that PGE(2) inhibits BSMC proliferation entailing a reduction of smooth muscle hyperplasia and thus protecting against the onset of airflow obstruction.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21458581     DOI: 10.1016/j.prostaglandins.2011.03.002

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  5 in total

Review 1.  Role of PGE2 in asthma and nonasthmatic eosinophilic bronchitis.

Authors:  Beatriz Sastre; Victoria del Pozo
Journal:  Mediators Inflamm       Date:  2012-03-19       Impact factor: 4.711

2.  Involvement of EP2 and EP4 Receptors in Eosinophilic Esophagitis: A Pilot Study.

Authors:  Franziska Durchschein; Andreas Eherer; Magdalena Grill; Eva M Sturm; Veronika Pommer; Cord Langner; Christoph Högenauer; Rudolf Schicho
Journal:  Dig Dis Sci       Date:  2019-04-15       Impact factor: 3.199

Review 3.  WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation - Updates in COVID-19.

Authors:  Philip W Rouadi; Samar A Idriss; Jean Bousquet; Tanya M Laidlaw; Cecilio R Azar; Mona S Al-Ahmad; Anahi Yañez; Maryam Ali Y Al-Nesf; Talal M Nsouli; Sami L Bahna; Eliane Abou-Jaoude; Fares H Zaitoun; Usamah M Hadi; Peter W Hellings; Glenis K Scadding; Peter K Smith; Mario Morais-Almeida; René Maximiliano Gómez; Sandra N Gonzalez Diaz; Ludger Klimek; Georges S Juvelekian; Moussa A Riachy; Giorgio Walter Canonica; David Peden; Gary W K Wong; James Sublett; Jonathan A Bernstein; Lianglu Wang; Luciana K Tanno; Manana Chikhladze; Michael Levin; Yoon-Seok Chang; Bryan L Martin; Luis Caraballo; Adnan Custovic; Jose Antonio Ortega-Martell; Erika Jensen-Jarolim; Motohiro Ebisawa; Alessandro Fiocchi; Ignacio J Ansotegui
Journal:  World Allergy Organ J       Date:  2021-11-22       Impact factor: 4.084

4.  An initial assessment of the involvement of transglutaminase2 in eosinophilic bronchitis using a disease model developed in C57BL/6 mice.

Authors:  Lan Chen; Shuyan Liu; Linzhuo Xiao; Kanyao Chen; Juanjuan Tang; Chuqin Huang; Wei Luo; Dominique Ferrandon; Kefang Lai; Zi Li
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379

Review 5.  E-type prostanoid receptor 4 (EP4) in disease and therapy.

Authors:  Viktoria Konya; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Journal:  Pharmacol Ther       Date:  2013-03-21       Impact factor: 12.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.